10 Best Penny Stocks to Buy for Long Term

8. AtaiBeckley Inc. (NASDAQ:ATAI)

On May 12, 2026, AtaiBeckley Inc. (NASDAQ:ATAI) reported Q1 EPS of (8c), versus the consensus estimate of (11c). Revenue totaled $954,000, versus the consensus estimate of $90,910. Co-Founder and CEO Srinivas Rao said the company’s $209.9M cash position is expected to fund operations through anticipated Phase 3 topline readouts for BPL-003 as the program advances into late-stage development. Rao added that the company’s near-term priorities include initiating the Phase 3 ReConnection program for BPL-003 during the current quarter, while VLS-01 continues progressing toward anticipated Phase 2 topline results later this year. Management also highlighted positive Phase 2a data for EMP-01 in Social Anxiety Disorder and said the company’s capital position, pipeline breadth, and upcoming clinical catalysts position it to pursue longer-term clinical and shareholder value creation.

Last month, Guggenheim raised the firm’s price target on AtaiBeckley Inc. (NASDAQ:ATAI) to $16 from $11 and kept a Buy rating on the shares. The firm said recent meetings with management reinforced its conviction in the BPL-003 program ahead of Phase 3 initiation this quarter.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing mental health treatments in the United States, Germany, and Canada.